BlogHeader.png

Quality and Regulatory Affairs Notification Letter

By now you should have been notified about our organizations next important step in the transition of joining AAIPharma Services Corp., a leading provider of drug product, development services and analytical testing, with Cambridge Major Laboratories, Inc., a world-class API drug developer and manufacturer. Effective March 16, 2016, our company will officially operate under the name Alcami [al-kuh-mee]. 

The previous name of our business units have been changed with state and local governments, in the D&B database, and with the FDA.  All of our sites within our organization are doing business as (dba) Alcami Corporation.  Following is a table that outlines how each site name / address / FEI / DUNS is identified with the FDA.

Name Address     FEI DUNS
Alcami Carolinas Corporation 2320 Scientific Park Dr., Wilmington, NC      1049418 831351445
Alcami Carolinas Corporation 1519 N 23rd St, Wilmington, NC      1049418 079646861
Alcami Carolinas Corporation 1726 N 23rd St, Wilmington, NC      1049418 832395235
Alcami Carolinas Corporation 4620 Creekstone Dr., Durham, NC      1000158582 832394535
Alcami Carolinas Corporation 4221 Faber Place Dr., Charleston, NC      1000110990 832394733
Alcami New Jersey Corporation 165 Fieldcrest Ave,  Edison, NJ      2210008 078392480
Alcami Missouri Corporation 6200 S. Lindbergh Blvd, St. Louis, MO      1942094 078392465
Alcami Wisconsin Corporation W130 N10497 Washington Dr., Germantown, WI      3004485164 054452136
Alcami Wisconsin Corporation W132 N10550 Grant Drive, Germantown, WI      3004485164 961717936

 

This name change has been submitted and accepted by the FDA. Further, we have successfully submitted the GDUFA Self-Identification under the above identified names for full year FY 2017. Important to note, while the above is a list of the legal names by site, all of our sites within our organization are doing businesses as (dba) Alcami Corporation.

To download a PDF of the Quality and Regulatory Affairs Notification Letter, please click here

We look forward to our continued partnership. If you have questions, please reach out to your primary contact person. 

Sincerely, 

Brian Dillion
BD_signiture.jpg
Vice President, Quality and Regulatory